LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aktien・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Geschlossen

14.43 5.02

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.96

Max

14.83

Schlüsselkennzahlen
By Trading Economics
Einkommen	-23M -14M
Verkäufe	-22M 72M
Gewinnspanne	-18.944
Angestellte	624
EBITDA	-23M -6.4M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+44.83% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-491M 2.3B
Vorheriger Eröffnungskurs	9.41
Vorheriger Schlusskurs	14.43

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

8.81 / 10.18 Unterstützung & Widerstand

Adaptive Biotechnologies Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Adaptive Biotechnologies Corp Prognose

Kursziel

By TipRanks

44.83% Vorteil

12-Monats-Prognose

Durchschnitt 21 USD 44.83%

Hoch 22 USD

Tief 20 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Adaptive Biotechnologies Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Adaptive Biotechnologies Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

8.81 / 10.18Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.